Pharmaceuticals, Biotechnology and Life Sciences
South Africa’s competition watchdog has launched an investigation into three drug companies accused of over-charging for cancer medicines, the agency’s chief said on Tuesday.
Astellas Pharma and Pfizer have amended the protocol for the registrational PROSPER trial to test the efficacy and safety of Xtandi in patients with non-metastatic (M0) Castration-Resistant Prostate Cancer (CRPC).
United States Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for Pfizer’s Xeljanz (tofacitinib citrate) 5 mg twice daily (BID) and XeljanzXR extended release 11 mg once daily use the treatment of adult patients with active psoriatic arthritis (PsA).
Karo Pharma has reached a second milestone from its collaboration with Pfizer on the RORgamma project amounting to $2 million.
Pfizer has decided to cancel listing of its stocks from the UK listing Authority List. The company said on Wednesday it also cancels trading on the main London Stock Exchange market.
Pfizer has reported 11% growth for full-year 2016 revenues, reaching $52.8 billion, including the business from Hospira and the legacy of Medivation. Net income for full year was $7,215 million which is up 4% from last years total net income of $6,960.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended Pfizer’s Xeljanz (tofacitinib citrate)…
Eli Lilly has bought a biotech company focusing on pain management, CoLucid Pharmaceuticals for approximately $960 million, ($46.50 per share)…
AstraZeneca has sold to Pfizer the commercialization and development rights of its late-stage small molecule antibiotics business, comprising the approved antibiotics Merrem, Zinforo and Zavicefta, and ATM-AVI and CXL, which are in clinical development.
Xbrane Biopharma has named Anders P. Wiklund as strategic advisor. He presently serves on the boards of EffRx Pharmaceuticals SA, Inspirion Delivery Technologies LLC, Life Medical AB and IRRAS AB.